Genmab A/S

Genmab develops antibody therapeutics for cancer and other diseases primarily in Denmark. The company markets DARZALEX for multiple myeloma and thyroid eye disease, as well as Amivantamab for gastric and esophageal cancer. Its products include treatments for blood cancers, AL amyloidosis, and solid tumors. The company also develops various antibodies for hematological malignancies and other diseases. Genmab has collaborations with Seagen, argenx, AbbVie, BioNTech, Janssen, and Novo Nordisk A/S. It operates pre-clinical programs and has a commercial license agreement with Seagen. The company was founded in 1999 and is headquartered in Copenhagen, Denmark.

Overview

Sector

Biotechnology

Target Price

1992.2 DKK

Current Price

1387.0 DKK

Potential

44%

Strengths

With an appreciation Potential of 38.59%, based on our fundamental analysis, it suggests the stock may be undervalued.
Current Price to Earnings Ratio (11.64) is lower than the sector mean (91.15).
Price to book ratio (2.49) is lower than the sector mean (24.44).
The company has low debt. Net Debt to EBITDA Ratio is -1.05 and it is lower than the sector mean.
The company has high returns. ROIC (20.60%) is higher than the sector mean (6.02%).
EV/EBITDA (9.81) is lower than the sector mean (85.60).
EV/EBIT (8.89) is lower than the sector mean.
Price to free cash flow (12.23) is lower than the sector mean.
Strong EBITDA Margin of 40.97%.

Weaknesses

Analysts expect revenues to decline in the coming year.

Key Financial Data

Indicator	Value
PER	11.2
EV/EBITDA	9.4
Price/Free Cash Flow'	11.8
ROIC	20.6%
Net Debt/EBITDA	-1.0